Industry
Biotechnology
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Loading...
Open
1.06
Mkt cap
29M
Volume
2M
High
1.11
P/E Ratio
-0.68
52-wk high
6.00
Low
1.01
Div yield
N/A
52-wk low
0.86
Portfolio Pulse from Benzinga Newsdesk
August 10, 2023 | 8:38 pm
Portfolio Pulse from Benzinga Insights
July 26, 2023 | 4:18 pm
Portfolio Pulse from Benzinga Newsdesk
July 19, 2023 | 12:04 pm
Portfolio Pulse from Benzinga Insights
June 15, 2023 | 1:07 pm
Portfolio Pulse from Benzinga Insights
June 12, 2023 | 1:07 pm
Portfolio Pulse from richadhand@benzinga.com
June 05, 2023 | 10:32 am
Portfolio Pulse from Benzinga Insights
May 30, 2023 | 7:00 pm
Portfolio Pulse from richadhand@benzinga.com
May 30, 2023 | 10:07 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.